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Abstract
Background: The identification of strategies to improve mutant CFTR function remains a key priority in the development of
new treatments for cystic fibrosis (CF). Previous studies demonstrated that the K
+ channel opener 1-ethyl-2-
benzimidazolone (1-EBIO) potentiates CFTR-mediated Cl
2 secretion in cultured cells and mouse colon. However, the
effects of 1-EBIO on wild-type and mutant CFTR function in native human colonic tissues remain unknown.
Methods: We studied the effects of 1-EBIO on CFTR-mediated Cl
2 secretion in rectal biopsies from 47 CF patients carrying a
wide spectrum of CFTR mutations and 57 age-matched controls. Rectal tissues were mounted in perfused micro-Ussing
chambers and the effects of 1-EBIO were compared in control tissues, CF tissues expressing residual CFTR function and CF
tissues with no detectable Cl
2 secretion.
Results: Studies in control tissues demonstrate that 1-EBIO activated CFTR-mediated Cl
2 secretion in the absence of cAMP-
mediated stimulation and potentiated cAMP-induced Cl
2 secretion by 39.266.7% (P,0.001) via activation of basolateral
Ca
2+-activated and clotrimazole-sensitive KCNN4 K
+ channels. In CF specimens, 1-EBIO potentiated cAMP-induced Cl
2
secretion in tissues with residual CFTR function by 44.4611.5% (P,0.001), but had no effect on tissues lacking CFTR-
mediated Cl
2conductance.
Conclusions: We conclude that 1-EBIO potentiates Cl
2secretion in native CF tissues expressing CFTR mutants with residual
Cl
2 channel function by activation of basolateral KCNN4 K
+ channels that increase the driving force for luminal Cl
2 exit. This
mechanism may augment effects of CFTR correctors and potentiators that increase the number and/or activity of mutant
CFTR channels at the cell surface and suggests KCNN4 as a therapeutic target for CF.
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Introduction
The early onset multiorgan disease cystic fibrosis (CF) is caused
by more than 1,800 mutations in the CFTR gene and remains the
most common fatal monogenetic disease in Caucasian populations
[1,2]. Therefore, the identification of strategies that improve
impaired function of mutant CFTR remains a high priority in the
development of causal therapies for patients with CF. The CFTR
gene encodes a cAMP-regulated Cl
2 channel that localizes to the
luminal membrane of epithelial cells, where it plays an important
role in transepithelial ion and fluid transport. CFTR mutations, via
different molecular mechanisms, can reduce the number, or
impair the regulation of CFTR Cl
2 channels inserted into the
apical cell membrane [3,4,5,6,7]. As a result, defective or reduced
CFTR-mediated Cl
2 secretion causes dehydration of epithelial
surfaces and dysfunction of many epithelial organs including the
small and large intestine, the pancreas, the hepato-biliary system,
and the airways [2,8,9].
Current pharmacological strategies to rescue and/or improve
CFTR function in CF focus on i) the development of CFTR
correctors that increase the number of apical membrane CFTR
Cl
2 channels by improving the processing or synthesis of mutant
CFTR; and ii) the development of potentiators that improve the
open probability (PO) of mutant CFTR Cl
2channels that are
delivered to the cell surface, but exhibit impaired gating [3,10]. In
a recent phase 2 clinical trial in CF patients carrying the gating
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CFTR-mediated Cl
2 secretion in nasal epithelia in vivo to levels of
,20% of normal [12,13]. A similar level of functional correction
was obtained in CF patients with CFTR nonsense mutations after
treatment with PTC124, a small molecule compound that
improves read through at premature stop codons to produce
full-length CFTR [14,15]. Previous studies on the correlation
between CFTR function and CF disease severity demonstrated
that detection of residual CFTR function in this range (,20% of
normal) in native nasal or intestinal epithelia was associated with a
less severe disease phenotype, but was not sufficient to prevent the
onset and progression of CF organ disease [16,17]. Therefore,
additional pharmacological strategies that further improve Cl
2
secretionthroughmutant CFTR channelsmayimprovetherapeutic
effects of current CFTR potentiator and corrector compounds.
Besides activation of luminal CFTR Cl
2 channels, CFTR-
mediated Cl
2 secretion relies on parallel activation of basolateral
Ca
2+- and cAMP-dependent K
+ channels that hyperpolarize the
membrane potential and generate the electrical driving force for
luminal Cl
2 exit [8,18,19]. A series of functional and genetic
studies in cultured cells and mice demonstrated that the Ca
2+-
activated intermediate conductance K
+ channel in the basolateral
membrane of colonocytes is encoded by KCNN4 and inhibited by
clotrimazole [20,21,22,23,24], whereas the cAMP-dependent K
+
channel is formed by the KCNQ1/KCNE3 complex and
inhibited by the chromanol 293B [25,26,27,28,29,30]. In this
context, previous studies in colonic cells (T84) and mouse colon
identified 1-ethyl-2-benzimidazolone (1-EBIO) as a compound
that potentiates CFTR-mediated Cl
2 secretion by coordinate
activation of the basolateral Ca
2+-activated K
+ channels KCNN4
(SK4, IK1) and luminal CFTR Cl
2 channels [31,32,33,34,35].
However, the effects of 1-EBIO on Cl
2 secretion mediated by
wild-type and mutant CFTR, and the role of KCNN4 and
KCNQ1/KCNE3 K
+ channels in native human colon have not
been studied.
We previously demonstrated that bioelectric measurements in
rectal biopsies mounted in perfused micro-Ussing chambers enable
sensitive assessment of CFTR function in native human tissues
[17,36]. In this study, we used this approach to determine the
effects of 1-EBIO on CFTR-mediated Cl
2 secretion in rectal
biopsies from non-CF individuals and CF patients carrying a wide
spectrum of CFTR mutations. First, we used protocols to study the
effect of 1-EBIO on the activity of luminal CFTR Cl
2 channels.
Second, we studied effects of 1-EBIO on basolateral Ca
2+-
activated and cAMP-dependent K
+ channels and determined
expression of KCNN4 and KCNQ1 K
+ channel transcripts in
human rectal biopsies. Finally, we determined the capacity of 1-
EBIO to potentiate Cl
2 secretion mediated by wild-type and
mutant CFTR. The results of our studies provide novel insights
into pharmacological modulation of mutant CFTR function in
native human CF epithelia and identified co-activation of the
basolateral K
+ channel KCNN4 as a potential strategy to augment
therapeutic effects of CFTR potentiator and corrector drugs.
Materials and Methods
Subjects
The study was approved by the Ethical Committees at the
University Hospitals of Heidelberg, Freiburg, Lisbon and Vienna,
and all subjects gave their written informed consent. For children
under 18, parents obtained detailed information and gave their
signed informed consent. The effects of 1-EBIO were studied in
rectal biopsies from 47 CF patients (31 PI, 16 PS; mean age
10.461.4 yr, range 3 mo to 47 yr) and 57 age-matched non-CF
controls (11.461.5 yr, range 6 mo to 45 yr) who were enrolled in
the study between 1999–2011 at the CF Centers at the University
Hospitals of Heidelberg, Freiburg, Lisbon and Vienna. The
diagnosis of CF was established by clinical symptoms characteristic
of CF, increased sweat Cl
2 concentrations ($ 60 mmol/L) and/
or detection of disease-causing mutations in both CFTR alleles
[37,38]. Exocrine pancreatic insufficiency (PI) was defined by a
history of malabsorption and fecal elastase E1 levels of ,200 mg/g
stool [39]. CFTR mutations were identified by sequential screening
by allele specific PCR (Elucigene CF20 kit, Cellmark, Abingdon,
UK) and denaturing gradient gel electrophoresis, followed by
automated DNA sequencing of the 27 exons of the CFTR gene
using the ABI Prism
TM BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems, Weiterstadt, Germany) as previously de-
scribed [17]. Genotypes of CF patients are summarized in table 1.
In all control subjects, sweat Cl
2 concentrations were normal
(,30 mmol/L) and genetic screening for 20 common CFTR
mutations was negative (Elucigene CF20 kit, Cellmark, Abingdon,
UK).
Ussing Chamber Experiments
Superficial biopsies of the rectal mucosa (,2 to 3 mm in
diameter) were collected by endoscopic forceps biopsy, immedi-
ately stored in ice cold tissue medium (medium 199 containing
Hank’s salts, L-glutamine and 25 mmol/L HEPES complemented
with 5 mmol/L glycine and 0.5 mmol/L Sodium-DL-b-hydroxy-
butyrate) and mounted in perfused micro-Ussing chambers (open
area ,0.95 mm
2) as previously described [19,40]. In brief, the
Table 1. CFTR genotypes of CF patients with no detectable
Cl
2 secretion (CFabsent) and residual Cl
2 secretion (CFresidual)i n
native rectal epithelia.
CFabsent CFresidual
CFTR genotype
Number of
individuals CFTR genotype
Number of
individuals
F508del/F508del 10 F508del/Y161C 1
F508del/W57X 1 F508del/V232D 1
F508del/G85E 3 F508del/R334W 2
F508del/120del23 1 F508del/T338I 1
F508del/182delT 1 F508del/I1234V 1
F508del/G542X 1 F508del/3272-26
A.G
1
F508del/A561E 1 F508del/3849+10
kb C.T
1
F508del/Y1092X 1 F508del/4005
+5727 A.G
1
F508del/N1303K 1 F508del/G576A 1
F508del/1525-1 G.A 2 N1303K/R334W 1
F508del/Q39X 1 F1052V/M1137R 1
F508del/Q552X 1 1898+3A .G/
1898+3A .G
1
G85E/G85E 1 R334W/3199del6 1
Q552X/R1162X 1 R334W/X 1
A561E/A561E 2 dele2,3/X 1
R764X/1717-1 G.A1
R1158X/2183AA.G1
R1158X/R560T 1
doi:10.1371/journal.pone.0024445.t001
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continuously with a solution of the following composition (mmol/
L): NaCl 145, KH2PO4 0.4, K2HPO4 1.6, D-glucose 5, MgCl2 1,
Ca-gluconate 1.3, pH 7.4, at 37uC. Experiments were performed
under open-circuit conditions. Values for the transepithelial
voltage (Vte) were referenced to the serosal surface of the
epithelium. Transepithelial resistance (Rte) was determined by
applying intermittent (1 s) current pulses (DI=0.5 mA). The
equivalent short circuit current (Isc’) was calculated according to
Ohm’s law from Vte and Rte (Isc’=V te/Rte) after appropriate
correction for fluid resistance [19,40].
Experimental Protocols and Analysis of Ussing Chamber
Experiments
Rectal tissues were equilibrated for 40 min in the presence of
amiloride (10 mmol/L, luminal) to block electrogenic Na
+
absorption and indomethacin (10 mmol/L, basolateral) to inhibit
prostaglandin E2 synthesis and endogenous cAMP formation.
Previous studies showed that under these experimental conditions,
CFTR activity is inhibited and Ca
2+-dependent activation with
carbachol (CCH, 100 mmol/L, basolateral) results in a transient
lumen-positive Isc’ response reflecting K
+ secretion that is
unmasked in the absence of anion secretion [8,19,40]. When
CFTR Cl
2 channels are activated under these conditions, Ca
2+-
dependent co-stimulation produces lumen-negative (Cl
2 secretory)
responses by activation of basolateral Ca
2+-activated K
+ channels
that increase the electrical driving force for luminal Cl
2 exit
[19,40,41]. To determine the effects of 1-EBIO on CFTR-
mediated Cl
2 secretion in the absence of cAMP-mediated
activation (indomethacin), we therefore measured the effects of
1-EBIO (500 mmol/L, basolateral) on basal Isc’ and CCH-induced
Isc’, and determined the effects of the CFTR inhibitor CFTRinh-
172 (20 mmol/L, basolateral) on 1-EBIO-induced responses.
To study the effect of 1-EBIO on basolateral Ca
2+-activated and
cAMP-dependent K
+ channels that generate the driving force
for CFTR-mediated Cl
2 secretion, control rectal tissues were
stimulated with 3-isobutyl-1-methylxanthine (IBMX; 100 mmol/
L, basolateral) and forskolin (1 mmol/L, basolateral) to obtain
maximal cAMP-mediated activation of CFTR, and the effects of
1-EBIO on cAMP-induced Isc’a n dC C H - i n d u c e dI sc’w e r e
measured before and after adding either clotrimazole (30 mmol/
L, basolateral), an inhibitor of the basolateral Ca
2+-activated K
+
channel KCNN4 [20,22,23], or 293B (10 mmol/L, basolateral),
an inhibitor of the cAMP-dependent heteromeric KCNQ1/
KCNE3 K
+ channel [25,26,28]. Dose-response curves for the
effects of 1-EBIO in the presence of cAMP-mediated activation
(IBMX/forskolin) were obtained by measuring the change in Isc’
induced by exposing tissues to increasing concentrations of 1-
EBIO (10
28 to 10
23 mol/L) and plotted as 1-EBIO-induced Isc’
normalized to the maximal 1-EBIO-induced Isc’( I sc’ max), and
EC50 values were determined by fitting dose-response data to the
Hill equation using Origin version 6.1 (OriginLab Corp.,
Northampton, MA).
To determine potentiator effects of 1-EBIO on CFTR-mediated
Cl
2 secretion in native control and CF rectal epithelia, tissues
were activated with IBMX and forskolin and effects of 1-EBIO on
cAMP-induced Isc’ and CCH-induced Isc’ were measured in
control tissues, CF rectal tissues with no detectable Cl
2 secretion
(CFabsent) and CF tissues with residual cAMP-mediated Cl
2
secretion (CFresidual). In the presence of cAMP stimulation, CCH
induced i) a transient monophasic lumen-negative (Cl
2 secretory)
response (control tissues), ii) a transient monophasic lumen-positive
(K
+ secretory) response (CFabsent tissues), or iii) a biphasic response
characterized by a lumen-positive peak followed by a lumen-
negative deflection (CFresidual) [17], and effects of 1-EBIO on
CCH-induced Cl
2 secretion were determined from lumen-
negative deflections (control and CFresidual tissues) or the lumen-
positive plateau (CFabsent tissues). In a subset of experiments, we
used CFTRinh-172 (20 mmol/L, luminal), and bumetanide
(100 mmol/L, basolateral), an inhibitor of the Na
+-K
+-2Cl
2
cotransporter (NKCC1), to block transepithelial Cl
2 secretion
[40]. For different experimental protocols, bioelectric measure-
ments were generally performed in one rectal biopsy per
individual. Occasionally, more than one sample from one
individual was studied by the same experimental protocol, and
data were averaged to obtain a single value for each individual
subject.
Reverse Transcriptase Polymerase Chain Reaction
Rectal biopsies were stored in RNAlater (Ambion, Darmstadt,
Germany) and total RNA was isolated using the RNeasy Mini Kit
(Quiagen, Hilden, Germany) and reverse transcribed into cDNA
using Superscript III (Invitrogen, Karlsruhe, Germany). Sequences
specific for KCNN4 (405 bp) and KCNQ1 (738 bp) were
amplified by PCR (94uC for 1 min, 60–62uC for 1 min, 72uC
for 2 min, 35 cycles) using the following custom made primers
(Eurofins MWG Operon, Ebersberg, Germany): KCNN4, 59-GA-
TTTAGGGGCGCCGCTGAC–39 (sense) and 59-CTTGCCCC-
ACATGGTGCCC–39 (antisense); KCNQ1, 59-TTCTGGATG-
GAGATCGTG-39 (sense) and 59-GCCTTCCGGATGTAGAT-
C–39 (antisense), as previously described [42,43]. PCR products
were visualized by 0.9% (w/v) agarose gel electrophoresis using a
100 bp DNA ladder as a DNA size marker, and sequences were
verified by sequencing (Seqlab, Go ¨ttingen, Germany).
Chemicals and Compounds
Amiloride, indomethacin, carbachol, IBMX, forskolin, bumet-
anide and clotrimazole were all obtained from Sigma (Deisenho-
fen, Germany). 1-EBIO was obtained from Tocris bioscience
(Avonmouth, UK), CFTRinh-172 from Calbiochem (Darmstadt,
Germany) and 293B from Hoechst (Frankfurt, Germany). All
chemicals used were of highest grade of purity available.
Statistical Analysis
Data were analyzed with SigmaStat version 3.1 (Systat
Software, Erkrath, Germany) and are reported as mean 6 SEM
(n= number of individuals studied). Statistical analyses were per-
formed using paired Student’s t test and Wilcoxon signed rank test
as appropriate, and P,0.05 was accepted to indicate statistical
significance.
Results
1-EBIO activates CFTR-dependent Cl
- secretion in native
rectal epithelia
To study the effects of 1-EBIO on luminal CFTR Cl
2 channels
in native human rectal epithelia, tissues were pretreated with
indomethacin to block endogenous cAMP-mediated CFTR
activation. Under these conditions, Vte and Isc’ approached ,zero
and cholinergic activation with CCH induced a monopha-
sic lumen-positive response reflecting luminal K
+ secretion
(Fig. 1 A,C,D) indicating that luminal CFTR Cl
2 channels
were inactive [19,40]. In control tissues, addition of 1-EBIO
resulted in a sustained lumen-negative Cl
2 secretory response
(DIsc’= 225.066.6 mA/cm
2, n=12, P=0.001) (Fig. 1 A,C). In
the presence of 1-EBIO, CCH induced a biphasic response with
the lumen-positive K
+ secretory peak followed by a lumen-
negative peak reflecting a transient increase in 1-EBIO-induced
1-EBIO Potentiates Mutant CFTR Function
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2 secretion (Fig. 1 A,D) [41]. Effects of 1-EBIO on basal and
CCH-induced Isc’ were completely reversible upon washout (Fig. 1
C,D). In rectal tissues from CF patients with two severe CFTR
mutations and no detectable cAMP-mediated Cl
2 secretion
(CFabsent) (Table 1), 1-EBIO failed to induce Cl
2 secretion
(DIsc’=20.760.8 mA/cm
2,n = 7 ,P=0.3) and had no effect on
CCH-induced Isc’ (Fig. 1 B,C,E). In rectal biopsies from the
control group, 1-EBIO-induced Cl
2 secretion was significantly
inhibited when tissues were pretreated with the CFTR inhibitor
CFTRinh-172 (Fig. 1 F). Similar, CCH-induced Cl
2 secretory
Figure 1. 1-EBIO activates CFTR-mediated basal and cholinergic Cl
2 secretion in human rectal biopsies. (A,B) Original recordings of
effects of 1-EBIO (500 mM, basolateral) on basal and carbachol-induced (CCH) transepithelial voltage (Vte) and transepithelial resistance (Rte) across
rectal biopsies from a control subject (A) and a CF patient carrying two severe CFTR mutations (R1158X/2183AA.G). (B) Experiments were performed
in the presence of amiloride and indomethacin. Lumen-positive Vte responses reflect K
+ secretion and lumen-negative responses reflect Cl
2 secretion.
Rte was determined from Vte downward deflections obtained by pulsed current injection. (C) Summary of effects of 1-EBIO on basal equivalent short-
circuit current (Isc’) in rectal biopsies from control subjects and CF patients with no detectable Cl
2 secretion (CFabsent). (D,E) Effects of 1-EBIO on CCH-
induced peak (open bars) and plateau (closed bars) Isc’ responses in control (D) and CFabsent rectal tissues (E). (F,G) Effect of CFTRinh-172 on 1-EBIO-
induced Cl
2 secretion (lumen-negative Isc’) under basal conditions (F) and on carbachol-induced (CCH) Cl
2 secretion in the presence of 1-EBIO (G) in
rectal biopsies from control subjects. Data are presented as mean6SEM. n=7–13 individuals per group. * P,0.001 and
{ P,0.01.
doi:10.1371/journal.pone.0024445.g001
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were inhibited by CFTRinh-172 (Fig. 1 G). Taken together, these
data provide pharmacologic and genetic evidence that 1-EBIO
activated luminal CFTR Cl
2 channel activity and transepithelial
Cl
2 secretion in native human rectal epithelia in the absence of
cAMP-mediated stimulation.
1-EBIO activates basolateral Ca
2+-dependent but not
cAMP-dependent K
+ channels in native rectal epithelia
Next, we determined the effect of 1-EBIO on basolateral K
+
channels in human rectal tissues. In these experiments, CFTR was
first activated by maximal cAMP stimulation (IBMX/forskolin) to
generate conditions under which basolateral K
+ channels became
limiting for CFTR-mediated Cl
2 secretion [8,30]. Under these
conditions, we then tested the effects of clotrimazole, an inhibitor
of the Ca
2+-activated KCNN4 K
+ channel (Fig. 2), and 293B, an
inhibitor of the cAMP-dependent KCNQ1/KCNE3 K
+ channel
complex (Fig. 3), on 1-EBIO-induced responses in control rectal
tissues.
Stimulation of tissues with IBMX and forskolin produced a
large and sustained Cl
2 secretory response that was significant-
ly increased by 1-EBIO (DIsc’=264.6613.5 mA/cm
2, n=17,
P=0.001) in a reversible and dose-dependent fashion
(EC50=583.8621.2 mmol/l; n=6) (Fig. 2 A,B,C). As expected
from previous studies, cholinergic co-activation induced a
transient increase in Cl
2 secretion reflecting an increase in the
driving force for CFTR-mediated Cl
2 secretion generated by
activation of basolateral K
+ channels [8,19]. CCH-induced Cl
2
secretory responses were significantly increased after tissues were
pretreated with 1-EBIO (Fig. 2 A,D). The effects of 1-EBIO on
cAMP-induced (IBMX/forskolin) and CCH-induced Cl
2 secre-
tion were completely inhibited when tissues were perfused with
clotrimazole (Fig. 2 A,B,D). RT-PCR analyses demonstrated that
transcripts encoding for the clotrimazole-sensitive Ca
2+-activated
K
+ channel KCNN4, which is pharmacologically activated by 1-
EBIO and responsible for driving Ca
2+-activated Cl
2 in mouse
colon [22,23,31], are expressed in native rectal tissues from control
subjects and CF patients (Fig. 2 E).
Perfusion of rectal tissues with 293B abolished cAMP-induced
Cl
2 secretion as expected [19], and RT-PCR demonstrated
expression of KCNQ1 transcripts in native rectal epithelia
(Fig. 3A,B,D). However, in contrast to clotrimazole (Fig. 2),
293B did neither inhibit 1-EBIO-induced Cl
2 secretion, nor the
augmentation of cholinergic Cl
2 secretion by 1-EBIO in the
presence of cAMP activation (Fig. 3A,B,C). Collectively, these
results indicated that 1-EBIO augments CFTR-mediated Cl
2
secretion in human colon in the presence of cAMP stimulation by
activation of the basolateral Ca
2+-activated KCNN4 K
+ channel,
but not the cAMP-dependent KCNQ1/KCNE3 K
+ channel
complex, and suggested that 1-EBIO may potentiate residual
CFTR-mediated Cl
2 secretion in CF tissues via this mechanism.
1-EBIO potentiates residual CFTR-mediated Cl
2 secretion
in CF rectal biopsies
To test if pharmacological co-activation of the Ca
2+-regulated
KCNN4 K
+ channel promotes CFTR-mediated Cl
2 secretion in
native CF tissues, we next determined the effects of 1-EBIO in
rectal biopsies from CF patients carrying a large spectrum
of CFTR mutations (Table 1). Following the equilibration in the
presence of amiloride and indomethacin, CF tissues were
stimulated with IBMX and forskolin to achieve maximal activation
of luminal CFTR Cl
2 channels and basolateral KCNQ1/KCNE3
K
+ channels, and co-stimulated with CCH to activate Ca
2+-
regulated KCNN4 K
+ channels, thus maximizing the driving force
for CFTR-mediated Cl
- secretion [8,19]. Based on Cl
2 secretory
responses observed with this protocol, tissues were stratified into
two groups, namely one group including tissues expressing residual
CFTR Cl
2 channel function (CFresidual) and another group with
no detectable Cl
2 secretion (CFabsent) [17]. The CF genotypes of
patients assigned to each group are summarized in table 1. Tissues
from age-matched control subjects were included in these studies
as a reference of wild-type CFTR function.
In the control group, cAMP-mediated stimulation induced a
large Cl
2 secretory response that was significantly increased by
cholinergic co-activation as expected [19] (Fig. 4 and 5). In the
CFabsent group, cAMP-mediated stimulation induced small lumen-
positive responses and co-activation with CCH produced a
monophasic lumen-positive Isc’ response reflecting K
+ secretion
[40] (Fig. 4 and 5). In the CFresidual group, cAMP-mediated
activation induced an attenuated but sustained lumen-negative
Cl
2 secretory response (Fig. 4 and 5). Consistent with previous
studies [17], co-activation of CFresidual tissues with CCH produced
biphasic responses with an initial lumen-positive (K
+ secretory)
deflection followed by a transient lumen-negative (Cl
2 secretory)
response (Fig. 4 and 5). Mean Cl
2 secretory responses in CFresidual
tissues accounted for ,34% of cAMP-mediated Cl
2 secretion and
,17% of CCH-induced Cl
2 secretion observed in control rectal
tissues (Fig. 5E,F). Similar to control tissues, Cl
2 secretory re-
sponses in CFresidual tissues were inhibited by bumetanide and
CFTRinh-172 demonstrating that residual cAMP- and CCH-
induced Cl
2 secretion was mediated by CFTR (Fig. 5A–D).
Addition of 1-EBIO significantly increased cAMP-mediated
Cl
2 secretion in control tissues (DIsc’=250.2613.1 mA/cm
2,
n=18, P=0.001) and CFresidual tissues (DIsc’=216.465.1 mA/
cm
2, n=12, P=0.001), but had no effect on CFabsent tissues (Fig. 4
and 5E). Of note, the percent increase in Cl
2 secretion induced by
1-EBIO was similar in the control group (39.266.7%, n=18,
P,0.001) and CFresidual group (44.4611.5%, n=12, P,0.001).
Further, 1-EBIO augmented CCH-induced Cl
2 secretory re-
sponses by 85.1612.2%, n=18, (P,0.001) in control tissues and
72.8621.4, n=7 (P,0.05) in CFresidual tissues, but failed to induce
Cl
2 secretion in CFabsent tissues (Fig. 4 and 5F). Taken together,
these data demonstrate that activation of basolateral Ca
2+-
activated KCNN4 K
+ channels by 1-EBIO potentiates CFTR-
mediated Cl
2 secretion induced by cAMP-mediated and cholin-
ergic activation in native CF rectal tissues that express mutant
CFTR proteins with residual Cl
2 channel function.
Discussion
This study provides important information on the pharmaco-
logical modulation of CFTR-mediated Cl
2 secretion in native
human normal and CF rectal epithelia. First, by using experi-
mental conditions under which CFTR Cl
2 channels were inactive,
we demonstrate that the benzimidazolone compound 1-EBIO
[31,32,33,34,35] activated CFTR-mediated Cl
2 secretion in nor-
mal rectal tissues in the absence of cAMP-mediated activation
(Fig. 1). As previously shown for the CFTR opener genistein [41],
1-EBIO-induced Cl
2 secretory responses were augmented by
cholinergic stimulation, consistent with parallel activation of
basolateral Ca
2+-activated K
+ channels that increase the driving
force for CFTR-mediated Cl
2 secretion [8,19]. The notion that 1-
EBIO acted as a CFTR Cl
2 channel opener in the absence of
cAMP-mediated activation was supported by the observations i)
that 1-EBIO-induced Cl
2 secretory responses were inhibited by
the CFTR inhibitor CFTRinh-172, and ii) that 1-EBIO failed to
induce Cl
2 secretion in rectal epithelia from CF patients carrying
1-EBIO Potentiates Mutant CFTR Function
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e24445Figure 2. 1-EBIO potentiates cAMP-mediated and cholinergic Cl secretion in human rectal biopsies and this effect is abrogated by
inhibition of Ca
2+-dependent K
+ channels with clotrimazole. (A) Original recording of effects of 1-EBIO (500 mM, basolateral) on cAMP-
induced Cl
2 secretion (IBMX/forskolin) and cholinergic co-activation (CCH), and effects of clotrimazole (30 mM, basolateral) on Cl
2 secretory
responses in a rectal biopsy from a control subject. Experiments were performed in the presence of amiloride, indomethacin and IBMX/forskolin. (B)
Summary of effects of 1-EBIO on cAMP-induced Cl
2 secretion and inhibition by clotrimazole in rectal tissues from control subjects. (C) Concentration-
response curve for 1-EBIO-induced Cl
2 secretion was determined in the presence of cAMP-mediated activation (IBMX/forskolin). (D) Effects of 1-EBIO
on CCH-induced Cl
2 secretion in the presence of IBMX/forskolin and inhibition by clotrimazole in control rectal tissues. Data are presented as
mean6SEM. n=17 individuals per group. *P,0.001. (E) RT-PCR analysis revealed transcripts of the clotrimazole-sensitive Ca
2+-activated K
+ channel
KCNN4 in rectal biopsies from control and CF subjects. The 405 bp KCNN4 fragment was only identified in the presence (+), but not in the absence of
reverse transcriptase (-).
doi:10.1371/journal.pone.0024445.g002
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Cl
2 channels in the apical cell membrane (Table 1) [7,17].
Second, our results show that 1-EBIO activated coltrimazole-
sensitive basolateral K
+ channels in rectal epithelia (Fig. 2,3). This
effect of 1-EBIO augmented CFTR-mediated Cl
2 secretion in
normal tissues when luminal CFTR Cl
- channels were fully
activated, as evidenced by a substantial increase in steady-state
and CCH-induced Cl
2 secretory responses in the presence of
Figure 3. 1-EBIO mediated augmentation of cAMP-induced and cholinergic Cl
2 secretion in human rectal biopsies does not depend
on 293B-sensitive cAMP-dependent K
+ channels. (A) Original recording of effects of 1-EBIO (500 mM, basolateral) on cAMP-induced Cl
2
secretion (IBMX/forskolin) and cholinergic co-activation (CCH), and effects of 293B (10 mM, basolateral) on Cl
2 secretory responses in a rectal biopsy
from a control subject. Experiments were performed in the presence of amiloride, indomethacin and IBMX/forskolin. (B, C) Summary of effects of 1-
EBIO on cAMP-induced (B) and CCH-induced Cl
2 secretion (C) in the absence and presence of 293B in rectal tissues from control subjects. Data are
presented as mean6SEM. n=19 individuals per group. *P,0.001. (D) RT-PCR analysis detected transcripts of the 293B-sensitive K
+ channel KCNQ1
(728 bp fragment) in the presence (+), but not in the absence of reverse transcriptase (-), in rectal biopsies from control and CF subjects.
doi:10.1371/journal.pone.0024445.g003
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2
secretion by 1-EBIO was completely abrogated when tissues were
pretreated with clotrimazole. In contrast, pretreatment of tissues
with 293B had no effect on 1-EBIO-induced Cl
2 secretion (Fig. 3).
This pharmacological profile, together with mRNA transcripts
analyses showing that both clotrimazole-sensitive KCNN4 K
+
channels, as well as 293B-sensitive KCNQ1 K
+ channels were
expressed in rectal tissues, support the concept that 1-EBIO
activates basolateral KCNN4 K
+ channels and thereby increases
the electrical driving force for CFTR-mediated Cl
2 secretion in
native human colon. The observation that 1-EBIO promoted
transepithelial Cl
2 secretion even in the absence of Ca
2+-
dependent stimulation (Fig. 2A–C) is consistent with previous
patch-clamp studies in cultured colonocytes (T84) and heterolo-
gous cells, which demonstrated that 1-EBIO activates KCNN4 K
+
channels at low levels of free Ca
2+ [31,44]. These results suggest
that pharmacological activation of basolateral KCNN4 K
+
channels can potentiate CFTR-mediated Cl
2 secretion in the
colon under basal conditions, as well as in the presence of
secretagogues activating cAMP- and Ca
2+ signaling pathways in
vivo. Taken together, our data showing a coordinate activation of
luminal CFTR Cl
2 channels and basolateral KCNN4 K
+
channels by 1-EBIO in human rectal epithelia are consistent with
previous results in colonic cells [22,31,32] and mouse colon
[23,33,34,35]. These results thus confirmed that this dual mode of
action of 1-EBIO is also operative in native human colon, and
formed the rationale for the hypothesis that 1-EBIO may
potentiate Cl
2 secretion in native CF tissues expressing CFTR
mutants with residual Cl
2 channel function.
We tested this hypothesis by studying the effects of 1-EBIO in
rectal tissues from CF patients carrying a wide spectrum of CF
genotypes (Table 1). These measurements focused on potentiator
effects of 1-EBIO in cAMP pre-stimulated tissues and demon-
strated that pharmacological activation of basolateral KCNN4 K
+
channels by 1-EBIO induced an ,44% increase in cAMP-
mediated Cl
2 secretion in CFresidual tissues, which expressed at
least one mild CFTR mutation producing Cl
2 channels with
residual function (Table 1, Fig. 4, 5). In contrast, consistent with
findings in the colon of Cftr-deficient (Cftr
-/-) mice [33,34], 1-
EBIO failed to induce Cl
2 secretion in CFabsent tissues expressing
two severe CFTR mutations that resulted in a lack of functional
CFTR Cl
2 channels in the luminal membrane of colonocytes
(Table 1, Fig. 4, 5), including rectal tissues from patients
homozygous for the common processing mutation F508del-
CFTR. However, it is noteworthy that 1-EBIO was able to
increase residual function of F508del-CFTR after low temperature
Figure 4. 1-EBIO potentiates residual CFTR-mediated Cl
2 secretion in CF rectal biopsies. (A–C) Original recordings of effects of cAMP-
mediated (IBMX/forskolin) and cholinergic (CCH) activation, and effects of 1-EBIO (500 mM, basolateral) on transepithelial voltage (Vte) and resistance
(Rte) in rectal tissues from a control subject (A), a CF patient with no detectable Cl
2 secretion (CFabsent; R1158X/2183AA.G) (B), and a CF patient with
residual Cl
2 secretion (CFresidual; F508del/Y161C), as evidence by lumen-negative Vte responses (C). Experiments were performed in presence of
amiloride and indomethacin. 1-EBIO potentiated cAMP-mediated and cholinergic Cl
2 secretion in control and CFresidual rectal tissues, but did not
induce Cl
2 secretion in the CFabsent tissue.
doi:10.1371/journal.pone.0024445.g004
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[45]. When viewed in combination, these results demonstrate that
1-EBIO, via activation of basolateral KCNN4 K
+ channels,
improves cAMP-mediated Cl
2 secretion in human CF tissues
expressing several CFTR mutants with residual Cl
2 channel
activity including F508del-CFTR when inserted into cell mem-
brane.
The relevance of these findings is underscored by recent results
driven from phase 2 clinical trials testing the CFTR potentiator
VX-770 [12] and the CFTR corrector PTC124 [15] in CF
patients carrying CFTR mutations responsive to these drugs. In
these studies, measurements of nasal potential difference indicated
that on average, both therapeutic strategies produced similar levels
of functional correction of CFTR-mediated Cl
2 secretion in the
range of ,20% of normal [12,13,15]. The results from previous
studies correlating CF disease severity with CFTR-mediated Cl
2
secretion in nasal and rectal epithelia predict that functional
correction to this level (i.e. ,20%) may ameliorate disease severity,
Figure 5. 1-EBIO potentiates residual CFTR-mediated Cl
2 secretion in CF rectal biopsies. (A–F) Summary of effects of bumetanide
(100 mM, basolateral) (A,B), CFTRinh-172 (20 mM, basolateral) (C,D) and 1-EBIO (500 mM, basolateral) (E,F) on cAMP-mediated (IBMX/forskolin) and
cholinergic (CCH) activation of equivalent short circuit current (Isc’) in rectal biopsies from control subjects, CF patients with no detectable Cl
2
secretion (CFabsent) and CF patients with residual Cl
2 secretion (CFresidual). All experiments were performed in the presence of amiloride and
indomethacin. Only lumen-negative peak responses or plateau responses are shown for cholinergic (CCH) activation. Data are presented as
mean6SEM. n=4–26 individuals per group. *P,0.001,
{P,0.01 and
"P,0.05.
doi:10.1371/journal.pone.0024445.g005
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data provide a proof-of-concept that pharmacological co-activa-
tion of basolateral KCNN4 K
+ channels substantially potentiates
residual CFTR function in native CF tissues (Fig. 4,5), and may
thus provide an opportunity to improve therapeutic effects of
current CFTR potentiator and corrector compounds developed
either to improve the open probability (PO) or to increase
the number of mutant CFTR Cl
2 channels in the apical cell
membrane [10,46,47]. However, no potent KCNN4 K
+ channel
openers have so far become available for clinical testing. While
previous structure-activity studies were able to identify benzimi-
dazolone derivatives that were up to 100-fold more potent in
activating KCNN4 than the reference compound 1-EBIO (EC50
,600 mmol/l), these improvements were not sufficient for clinical
development [48]. We expect that recent developments in
functional high-throughput screening including cell-based fluores-
cent screens for K
+ channel activity will enable the identification of
new KCNN4 K
+ channel activators that may be useful as lead
compounds for CF drug development [46,47,49].
We previously demonstrated that transepithelial bioelectric
measurements in rectal biopsies provide a sensitive tool to detect
residual CFTR function in native tissues from individual CF
patients carrying mild CFTR mutations, and that the magnitude of
residual residual CFTR function correlated with clinical outcomes
including age at diagnosis, exocrine pancreatic function, and lung
function [17]. In these prior studies, the magnitute of normal
cAMP-induced CFTR-mediated Cl
2 secretion detected with our
modified micro-Ussing chambers in rectal tissues from healthy
individuals was ,5 to 40-fold greater than values reported with
other experimental setups [17,36,50,51] indicating that our
protocols detected CFTR function at high fidelity. However, the
sensitivity of this assay to detect effects of CFTR potentiators and
correctors was not known. Our present results indicate that this
technique provides a sensitive tool to detect potentiator effects on
low levels of residual CFTR function in individual CF patients
(Fig. 4,5). These data suggest that assessment of CFTR function in
rectal biopsies may provide a sensitive biomarker to evaluate
effects of CFTR potentiator and corrector drugs in future clinical
trials aimed at correcting the CFTR-associated defects [52]. We
expect that this new outcome measure, together with bioelectric
measurments of CFTR function in sweat glands and nasal
epithelia [13,53], will help to determine the level of functional
correction that is required in different organ systems to achieve
therapeutic benefits in CF patients. In the future, assessment of
CFTR function in rectal biopsies and pre-testing of drugs ex vivo
may also aid individualized CF therapy. In this context, this
measurement could help to stratify CF patients carrying CFTR
mutations with unknown functional consequences for treatment
with CFTR potentiator or corrector drugs, and also pre-assess
which patients will be ‘responders’ to a given drug by determining
its therapeutic effects on CFTR function directly in native tissues
from each individual CF patient.
In summary, we demonstrate that 1-EBIO activates CFTR-
mediated Cl
2 secretion in native human colon by coordinate
activation of luminal CFTR Cl
2 channels and basolateral
Ca
2+-activated KCNN4 K
+ channels, and that this mode of
action potentiates residual cAMP-mediated Cl
2 secretion in
native CF rectal tissues expressing CFTR mutants that retain
residual Cl
2 channel function. Our results suggest that
pharmacological co-activation of KCNN4 K
+ channels may
augment therapeutic effects of CFTR potentiator and correc-
tor compounds that are currently in active preclinical and
clinical development, and suggest KCNN4 as a therapeutic
target for CF.
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